Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings

Pfizer (PFE) is scheduled to report Q2 2025 earnings on August 5th, with consensus estimates at $13.78 billion in sales and $0.58 EPS. While the company faces ongoing revenue headwinds from declining COVID-19 product sales and the Inflation Reduction Act's impact on drug pricing, growth in key non-COVID assets like Vyndaqel and Padcev, alongside benefits from the Seagen acquisition and $7.7 billion in planned cost savings by 2027, are expected to drive future EPS growth. Despite an upcoming loss of exclusivity cliff, PFE presents an attractive valuation at 7.61x forward P/E, significantly below the industry average, complemented by a dividend yield exceeding 7%.

Analysis

Pfizer (PFE) is approaching its Q2 2025 earnings report on August 5 with consensus estimates of $13.78 billion in sales and $0.58 EPS. The company is in a significant transition phase, moving beyond its COVID-19 revenue peak while navigating notable headwinds. Key challenges include pricing pressures from the Inflation Reduction Act (IRA), which is expected to soften sales of major products like Eliquis and Ibrance, and declining demand for its COVID-19 treatments. Despite these pressures, growth in its non-COVID portfolio, particularly from Vyndaqel, Padcev, Lorbrena, and Nurtec, is anticipated to provide a partial offset. The recent Seagen acquisition has fortified its oncology pipeline, with Padcev's strong demand being a key highlight. Management's strategy hinges on a substantial cost-saving initiative targeting $7.7 billion in efficiencies by 2027, which is projected to support EPS growth even as top-line expansion remains muted ahead of a major loss of exclusivity cliff in 2026-2030. From a valuation perspective, PFE appears attractive, trading at a forward P/E of 7.61x, a significant discount to its 5-year mean of 10.82x and the industry average of 14.30x. This, combined with a high dividend yield exceeding 7%, underpins the stock's appeal to value and income-focused investors, despite its 7.5% year-to-date share price decline.

Key Decisions for Investors

• Given the stock's forward P/E of 7.61x, which is well below the industry average, and a dividend yield over 7%, PFE presents a compelling case for value and income-oriented investors.
• Investors should monitor the upcoming Q2 earnings for confirmation of the growth trajectory in non-COVID assets like Padcev and Vyndaqel, as their performance is critical to offsetting declines in legacy products and validating the post-COVID transition narrative.
• While the company's history of earnings surprises and a positive Earnings ESP suggest a potential beat, focus should be on management's guidance regarding the impact of the IRA and progress on the $7.7 billion cost-restructuring program, as these are key drivers for future EPS growth.
• The significant challenges, including the impending 2026-2030 patent cliff, suggest that PFE should be viewed as a long-term position where the thesis depends on successful pipeline execution and cost management rather than near-term top-line expansion.